Data from the first human trial presented at the International AIDS Society"s conference in Cape Town, South Africa, showed GlaxoSmithKline PLC"s experimental AIDS drug, S/GSK1349572, decreased the virus to undetectable levels in 70 percent of the 35 patients in the study and none of the patients showed signs of drug resistance.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지